# Fortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference Canonical URL: https://biopharmsignal.com/news/FBIO/fortress-biotech-to-participate-in-the-h-c-wainwright-2nd-annual-royalty-company-virtual-conference Ticker: FBIO Company: Fortress Biotech Source: Fortress Biotech Published: 2026-05-04 12:30 EST Original Source URL: https://www.fortressbiotech.com ## Summary

MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today ann ## Article Body MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference, taking place on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 12:30pm ET. To register for the conference, visit https://hcwevents.com/royalty-company-conference. About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Nationwide Children’s Hospital, Columbia University, Dana-Farber Cancer Center and Sentynl Therapeutics. For more information, visit www.fortressbiotech.com. Company Contact: Jaclyn Jaffe Fortress Biotech, Inc. (781) 652-4500 ir@fortressbiotech.com Media Relations Contact: Tony Plohoros 6 Degrees (908) 591-2839 tplohoros@6degreespr.com Source: Fortress Biotech, Inc. ## Recent Company News - 2026-05-19 20:45 EST — [Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference](https://biopharmsignal.com/news/FBIO/journey-medical-corporation-to-participate-in-a-g-p-s-annual-virtual-healthcare--cca64eaf) — Source: Fortress Biotech - 2026-05-18 12:30 EST — [Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference](https://biopharmsignal.com/news/FBIO/fortress-biotech-to-participate-in-a-g-p-s-annual-virtual-healthcare-conference) — Source: Fortress Biotech - 2026-05-14 20:10 EST — [Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/FBIO/fortress-biotech-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights) — Source: Fortress Biotech - 2026-05-13 20:01 EST — [Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights](https://biopharmsignal.com/news/FBIO/journey-medical-corporation-reports-first-quarter-2026-financial-results-and-recent-corporate-highlights) — Source: Fortress Biotech - 2026-05-06 20:01 EST — [Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026](https://biopharmsignal.com/news/FBIO/journey-medical-corporation-to-announce-first-quarter-2026-financial-results-on-may-13-2026) — Source: Fortress Biotech ## Related News - 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8) - 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05) - 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004) - 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7) - 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)